NCT03498937

Brief Summary

The study aims to evaluate the impact of transcranial direct current stimulation (tDCS) on impulsiveness of adults suffering from Borderline Personality Disorder. Short- and long-term effects are assessed by electroencephalography (EEG) records, experimental tasks and self-rated scales.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2019

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 9, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 17, 2018

Completed
1 year until next milestone

Study Start

First participant enrolled

May 1, 2019

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

March 7, 2019

Status Verified

April 1, 2018

Enrollment Period

1.1 years

First QC Date

April 9, 2018

Last Update Submit

March 6, 2019

Conditions

Keywords

Borderline Personality DisorderImpulsive behaviorSuicidal behaviorCognitive controltDCSNoninvasive brain stimulation

Outcome Measures

Primary Outcomes (1)

  • EPs during BART

    Amplitude variation of evoked potentials (EPs) detected by electroencephalography (EEG) during the Balloon Analogue Risk Task (BART), assessing risk-taking behavior. Variation will be obtained by comparing records before beginning of stimulation sessions with 5, 12 and 30 days after active and/or sham tDCS.

    Baseline (Day 0), Day 5, Day 12 and Day 30 post-tDCS

Secondary Outcomes (7)

  • BIS-10 scores

    Baseline (Day 0), Day 5, Day 12 and Day 30 post-tDCS

  • HDRS scores

    Baseline (Day 0), Day 5, Day 12 and Day 30 post-tDCS

  • UPPS-P scores

    Baseline (Day 0), Day 5, Day 12 and Day 30 post-tDCS

  • MADRS scores

    Baseline (Day 0), Day 5, Day 12 and Day 30 post-tDCS

  • C-SSRS scores

    Baseline (Day 0), Day 5, Day 12 and Day 30 post-tDCS

  • +2 more secondary outcomes

Study Arms (2)

Group 1

EXPERIMENTAL

Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 active tDCS sessions, followed by 10 sham tDCS sessions

Device: Active tDCSDevice: Sham tDCS

Group 2

EXPERIMENTAL

Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 sham tDCS sessions, followed by 10 active tDCS sessions

Device: Active tDCSDevice: Sham tDCS

Interventions

10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC

Also known as: Starstim® (Neuroelectrics, Spain)
Group 1Group 2
Sham tDCSDEVICE

10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC

Also known as: Starstim® (Neuroelectrics, Spain)
Group 1Group 2

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Man or woman older than 18 years old
  • Right-handed
  • Signed Informed Consent form
  • Subject affiliated to or beneficiary from a French social security regime
  • Inpatient or outpatient at the Adult Psychiatry Service
  • Diagnosis of Borderline Personality Disorder according to the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and confirmation by the Structured Clinical Interview for DSM Disorders (SCID-II)
  • Absence of addictive comorbidities (except: tobacco, tea, coffee)
  • Absence of severe progressive neurologic and/or somatic pathologies (specially tumors, degenerative diseases)

You may not qualify if:

  • Younger than 18 years old
  • Left-handed
  • Subject under measure of protection or guardianship of justice
  • Presence of psychiatric comorbidities (chronic psychosis, Bipolar Disorder)
  • Subject beneficiary from a legal protection regime
  • Subject unlikely to cooperate or low cooperation stated by investigator
  • Subject not covered by social security
  • Pregnant woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

CHU Besancon

Besançon, Franche-Comte, 25000, France

Location

Pôle Hospitalo-Universitaire de Psychiatrie du Grand Nancy

Nancy, France

Location

Centre Hospitalier Spécialisé de Rouffach

Rouffach, France

Location

Related Publications (2)

  • Storebo OJ, Stoffers-Winterling JM, Vollm BA, Kongerslev MT, Mattivi JT, Jorgensen MS, Faltinsen E, Todorovac A, Sales CP, Callesen HE, Lieb K, Simonsen E. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020 May 4;5(5):CD012955. doi: 10.1002/14651858.CD012955.pub2.

  • Teti Mayer J, Nicolier M, Gabriel D, Masse C, Giustiniani J, Compagne C, Vandel P, Pazart L, Haffen E, Bennabi D. Efficacy of transcranial direct current stimulation in reducing impulsivity in borderline personality disorder (TIMBER): study protocol of a randomized controlled clinical trial. Trials. 2019 Jun 10;20(1):347. doi: 10.1186/s13063-019-3427-z.

MeSH Terms

Conditions

Borderline Personality DisorderImpulsive Behavior

Condition Hierarchy (Ancestors)

Personality DisordersMental DisordersBehavior

Study Officials

  • Djamila BENNABI, MD PhD

    Centre Hospitalier Universitaire de Besancon

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Djamila BENNABI, MD PhD

CONTACT

Magali NICOLIER, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 9, 2018

First Posted

April 17, 2018

Study Start

May 1, 2019

Primary Completion

June 1, 2020

Study Completion

December 1, 2020

Last Updated

March 7, 2019

Record last verified: 2018-04

Data Sharing

IPD Sharing
Will not share

Locations